Differential Nrf2 expression between glioma stem cells and non-stem-like cells in glioblastoma

Oncology Letters

Volumn 7, Issue 3, 2014, Pages 693-698

  Zhu, Jianhong ^a   Wang, Handong ^a   Ji, Xiangjun ^a   Zhu, Lin ^a   Sun, Qing ^a   Cong, Zixiang ^a   Zhou, Yuan ^a   Liu, Huandong ^b   Zhou, Mengliang ^a  

^a JINLING HOSPITAL   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Glioblastoma; Glioma stem cell; Nuclear factor erythroid 2 related factor 2

Indexed keywords

CD133 ANTIGEN; NESTIN; TRANSCRIPTION FACTOR NRF2;

ARTICLE; CANCER CELL CULTURE; CANCER STEM CELL; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GLIOBLASTOMA; GLIOMA STEM CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; NEURAL STEM CELL; OXIDATIVE STRESS; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 84892970411     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1760     Document Type: Article

References (30)

1. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY and Olson JJ: Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin60: 166-193, 2010.
2. Vescovi AL, Galli R and Reynolds BA: Brain tumour stem cells. Nat Rev Cancer6: 425-436, 2006.
3. Huang Q, Zhang QB, Dong J, Wu YY, Shen YT, Zhao YD, ZhuYD, Diao Y, Wang AD and Lan Q: Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro. BMC Cancer8: 304, 2008.
4. He H, Li MW and Niu CS: The pathological characteristics of glioma stem cell niches. J Clin Neurosci19: 121-127, 2012.
5. Johannessen TC, Bjerkvig R and Tysnes BB: DNA repair and cancer stem-like cells-potential partners in glioma drug resistance? Cancer Treat Rev34: 558-567, 2008.
6. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature444: 756-760, 2006.
7. Kang MK and Kang SK: Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma. StemCellsDev16: 837-847, 2007.
8. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, ShiQ, Cao Y, Lathia J, McLendon RE, etal: Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. CancerCell15: 501-513, 2009.
9. Heddleston JM, Wu Q, Rivera M, Minhas S, Lathia JD, SloanAE, Iliopoulos O, Hjelmeland AB and Rich JN: Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential. Cell Death Differ19: 428-439, 2012.
10. Soeda A, Park M, Lee D, Mintz A, Androutsellis-TheotokisA, McKay RD, Engh J, Iwama T, Kunisada T, Kassam AB, etal: Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene28: 3949-3959, 2009.
11. Kensler TW, Wakabayashi N and Biswal S: Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. AnnuRevPharmacolToxicol47: 89-116, 2007.
12. Zhao F, Wu T, Lau A, Jiang T, Huang Z, Wang XJ, Chen W, WongPK and Zhang DD: Nrf2 promotes neuronal cell differentiation. Free Radic Biol Med47: 867-879, 2009.
13. Kato K, Takahashi K, Monzen S, Yamamoto H, Maruyama A, Itoh K and Kashiwakura I: Relationship between radiosensitivity and Nrf2 target gene expression in human hematopoietic stem cells. Radiat Res174: 177-184, 2010.
14. Bobilev I, Novik V, Levi I, Shpilberg O, Levy J, Sharoni Y, Studzinski GP and Danilenko M: The Nrf2 transcription factor is a positive regulator of myeloid differentiation of acute myeloid leukemia cells. Cancer Biol Ther11: 317-329, 2011.
15. Zhou Y, Wang HD, Zhu L, Cong ZX, Li N, Ji XJ, Pan H, WangJW and Li WC: Knockdown of Nrf2 enhances autophagy induced by temozolomide in U251 human glioma cell line. OncolRep29: 394-400, 2013.
16. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U and Beier CP: CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res67: 4010-4015, 2007.
17. Strojnik T, Røsland GV, Sakariassen PO, Kavalar R and LahT: Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival. Surg Neurol68: 133-144, 2007.
18. Närvä E, Rahkonen N, Emani MR, Lund R, Pursiheimo JP, NästiJ, Autio R, Rasool O, Denessiouk K, Lähdesmäki H, etal: RNA-binding protein L1TD1 interacts with LIN28 via RNA and is required for human embryonic stem cell self-renewal and cancer cell proliferation. Stem Cells30: 452-460, 2012.
19. Sharma V, Dixit D, Ghosh S and Sen E: COX-2 regulates the proliferation of glioma stem like cells. Neurochem Int59: 567-571, 2011.
20. Mizrak D, Brittan M and Alison MR: CD133: molecule of the moment. J Pathol214: 3-9, 2008.
21. Shmelkov SV, St Clair R, Lyden D and Rafii S: AC133/CD133/Prominin-1. Int J Biochem Cell Biol37: 715-719, 2005.
22. Folkins C, Shaked Y, Man S, Tang T, Lee CR, Zhu Z, HoffmanRM and Kerbel RS: Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. CancerRes69: 7243-7251, 2009.
23. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J and Dirks PB: Identification of a cancer stem cell in human brain tumors. Cancer Res63: 5821-5828, 2003.
24. Kondo T, Setoguchi T and Taga T: Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. ProcNatlAcadSciUSA101: 781-786, 2004.
25. Pan H, Wang H, Zhu L, Wang X, Cong Z, Sun K and Fan Y: The involvement of Nrf2-ARE pathway in regulation of apoptosis in human glioblastoma cell U251. Neurol Res35: 71-78, 2013.
26. Alam J, Stewart D, Touchard C, etal: Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J Biol Chem274: 26071-26078, 1999.
27. Fan H, Guo H, Zhang IY, Liu B, Luan L, Xu S, Hou X, Liu W, Zhang R, Wang X and Pang Q: The different HMGA1 expression of total population of glioblastoma cell line U251 and glioma stem cells isolated from U251. Brain Res1384: 9-14, 2011.
28. Zhang M, Song T, Yang L, Chen R, Wu L, Yang Z and Fang J: Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. JExpClinCancerRes27: 85, 2008.
29. Motohashi H and Yamamoto M: Nrf2-Keap1 defines a physiologically important stress response mechanism. TrendsMolMed10: 549-557, 2004.
30. Yang L, Lin C, Wang L, Guo H and Wang X: Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implications. ExpCellRes318: 2417-2426, 2012.